Studies on live attenuated mumps vaccine. II. Follow-up study on the efficacy of Biken Vaccine.
Clinical and serological follow-ups were made on 18 children for 3 years and on another 18 children for 4 years, after immunization against mumps by attenuated mumps vaccine; Biken vaccine. To evaluate the protective efficacy of the vaccine, matched controls were studied during the same period. Serological examinations revealed that 77% of the vaccinees and 93% of the controls were infected with mumps after close contacts with mumps patients. Regular mumps was contracted by 88% of the controls, but none of the vaccinees. There was no substantial decrease in the antibody titers in unexposed vaccinees after vaccination.
D000914:Antibodies, Viral / Q000096:biosynthesis; D002648:Child; D002675:Child, Preschool; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006386:Hemagglutination Tests; D006801:Humans; D007114:Immunization; D009107:Mumps / Q000276:immunology / Q000517:prevention & control*; D009108:Mumps Vaccine; D009109:Mumps virus / Q000276:immunology; D009500:Neutralization Tests; D014613:Vaccines, Attenuated
D000914:Antibodies, Viral; D009108:Mumps Vaccine; D014613:Vaccines, Attenuated